Institute of Science Tokyo Hospital

Tokyo 113-8519

9 studies enrolling now · 14 studies all time

What they study most

APDS, Active Idiopathic Inflammatory Myopathy, Antisynthetase Syndrome, Crohn's Disease, Dermatomyositis, Follicular Lymphoma, Hypochondroplasia, Immune-Mediated Necrotizing Myopathy, Large B-cell Lymphoma, Liver Fibrosis, Metabolic Dysfunction Associated Steatohepatitis, Metabolic Dysfunction Associated Steatohepatitis (MASH)

Studies at this site

• A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis — Recruiting now
• LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis — Recruiting now
• A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months — Recruiting now
• A Multicenter Multinational Observational Study of Children With Hypochondroplasia — Recruiting now
• A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy — Enrolling by invitation
• Pediatric Patients Aged 1 to 6 Years With APDS — Running, not enrolling
• Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel — Available (expanded access)
• A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow — Running, not enrolling
• A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day — Running, not enrolling
• Pediatric Patients Aged 4 to 11 Years With APDS — Running, not enrolling
• Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia — Running, not enrolling
• Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia — Enrolling by invitation